AYTU Aytu BioPharma
- 3.1900
- -0.0100-0.31%
- 3.1500
- -0.0400-1.25%
Aytu BioPharma News
Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
Q3 2024 Aytu Biopharma Inc Earnings Call
Aytu BioPharma | 10-Q: Quarterly report
Earnings Call Summary | Aytu BioPharma(AYTU.US) Q3 2024 Earnings Conference
The following is a summary of the Aytu BioPharma, Inc. (AYTU) Q3 2024 Earnings Call Transcript:Financial Performance:Aytu reported an ADHD portfolio revenue growth of 49% in comparison to the fiscal 2
Aytu BioPharma, Inc. (AYTU) Q3 2024 Earnings Call Transcript
Aytu BioPharma, Inc. (AYTU) Q3 2024 Earnings Call Transcript
Aytu BioScience up 5% as Quarterly Results Beat on Both Lines
Express News | Aytu Biopharma Q3 Gross Profit USD 11.7 Million
Express News | Aytu Biopharma Q3 Net Income USD -2.9 Million
Express News | Aytu Biopharma Q3 EPS USD -0.52
Express News | Aytu Biopharma Q3 Revenue USD 18 Million
Express News | Aytu Biopharma Q3 Adjusted Ebitda USD 15.4 Million
Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results
Q3 2024 ADHD Portfolio net revenue up 49% compared to Q3 2023Q3 2024 adjusted EBITDA 1 improved by $7.0 million compared to Q3 2023TTM March 2024 operating income of $7.3 million for the Rx BusinessTT
Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024
DENVER, CO / ACCESSWIRE / May 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial
Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now
Aytu BioPharma Second Quarter 2024 Earnings: Beats Expectations
Earnings Call: Aytu BioPharma Achieves First Positive Operating Income
Earnings Call Summary | Aytu BioPharma(AYTU.US) Q2 2024 Earnings Conference
The following is a summary of the Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript:Financial Performance:Aytu BioPharma achieved $5.1 million in adjusted EBITDA, up from the previous year'
Aytu BioPharma Q2 2024 GAAP EPS $(0.04) Beats $(0.25) Estimate, Sales $22.93M Beat $21.75M Estimate
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.25) by 84 percent. The company reported quarterly sales of $22.93 million
Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, Vs. Street Est of $21.75M
04:07 PM EST, 02/14/2024 (MT Newswires) -- Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
Q2 2024 operating income of $2.4 millionQ2 2024 net loss of $0.2 million and adjusted EBITDA1 of $5.1 millionQ2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted E
Analysis
Price Target
No Data
